Fill in the detail,
"The agreement will see at least 60 Pfizer representatives marketing Vascepa to between 6,000 and 10,000 family doctors in Canada (out of approximately 45,000), who are responsible for between 70 and 80 per cent of CV script volume within its target cohort, while HLS will continue to leverage its its in-house salesforce of roughly 30 people to market Vascepa to over 2,500 cardiologists and other specialists across Canada."